|
|
| Courses | Phar 5822 |
|
| I. General Definitions | ||
| This
research fellowship
is a directed,
highly individualized postgraduate training program designed to prepare
the participant to become a clinical scientist.
This training will prepare successful candidates to qualify for
faculty positions in academic settings, research positions in the private
sector as well as numerous other opportunities which utilize the
scientific and critical thinking skills obtained through this experience. The program is offered within the Experimental and Clinical
Pharmacology Department at the University Of Minnesota College Of Pharmacy
and can be taken in conjunction with the Ph.D. program track in
Experimental and Clinical Pharmacology. |
||
|
II. Eligibility and Goals of the Fellowship Program |
||
| This
experience is intended to be a two-year fellowship program with the goals
of further developing the candidate’s knowledge base of cardiovascular
pharmacotherapy and the skills necessary to become a clinical scientist. These skills include scientific and grant writing skills,
data collection, analysis, and interpretation skills and data presentation
skills. The program focuses
on clinical experimental and cardiovascular pharmacotherapy research with
an emphasis on the pharmcodynamics of cardiovascular agents including
metabolic and pharmacogenetic basis of their response.
Exposure to analytical and pharmacogenetic (molecular biology)
techniques along with didactic coursework relevant to the research
projects should be expected in this training program.
To a limited degree, the candidate will be afforded the opportunity
to provide didactic and clinical instruction to Pharm.D. Candidates in the
U of MN program.
An ideal candidate would have completed one year of a residency and would be willing to commit to a two-year fellowship training experience. For specific candidates with exceptional clinical training or previous scientific training, a two-year fellowship may be entertained without the pre-requisite of a clinical residency. |
||
| III. Faculty Involved with the Program | ||
| Cooperation between members of the Experimental and Clinical Pharmacology Department, Division of Cardiology and School of Public Health at the University of Minnesota is key to the success of this program and excellent opportunity for the applicant. The primary advisor for the fellow applicant is Robert J. Straka, Pharm.D. FCCP, however depending on the projects undertaken, a co-advisor from another appropriate medical area may also be appointed. | ||
| IV. Overview of the Program | ||
|
Although
highly individualized, a typical program may include the following
activities over a two-year period. Section A
– Research Activities:
The candidate will actively participate in each and
every aspect of conducting clinical research.
The nature of the projects range from clinical oriented studies
such as Phase II, III and IV studies to more basic research related
projects depending on the candidate’s interest and opportunities at the
time of application. Opportunities exists for interested students to
develop laboratory based analytical skills (primary HPLC) and basic
molecular biology techniques such as RFLP, PCR etc. based on the projects
being conducted at that time. Dr.
Straka’s laboratory is located within the Department's Core Lab facility
and works in cooperation with the Core Lab Director,
lab technicians other labs across the U of MN campus.
|
||
| V. Funding for the Program | ||
| Funding for the Program:
Funding
for the fellowship has been based on dollars generated through funded
research projects. Recently,
the research fellow was funded by the NIH (GOLDN
Study). Historically,
funding has come from sources including a competitive pharmacogenetics
fellowship Award from the ACCP Research Institute as well as funding from
private sources relating to other grants or research projects.
Application for training grants through the NIH is strongly
encouraged. Stipends vary by experience level but are generally approximately $33,000 per year with tuition, vacation and healthcare benefits. |
||
| VI. Application Information | ||
| Application Information: Generally, the earlier completed applications are received, the better off all parties are. This makes the interviewing schedule and decision process most efficient. I would generally expect completed applications to be received by mid-February 2007. Although exceptions are considered on a case-by-case basis, this goal date permits timely evaluations and considerations by all parties concerned. Prospective applicants are strongly encouraged to notify intent to apply as early as possible. Current Research Areas:
Application Procedure: Generally we ask for:
|
||
| VII. Historical Summary of Past Fellows and Current Status | ||
| Click Here to View the Current Status of Past Fellows/Residents | ||
|
| [Phar 5822 Homepage] [College of Pharmacy Homepage] [University of Minnesota Homepage] |
| The University of Minnesota is an equal opportunity educator and employer. The
views and opinions expressed in this page are strictly those of the page author. The
contents of this page have not been reviewed or approved by the University of Minnesota. |
